COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE: CANADIAN PERSPECTIVE

被引：0
|
作者：
El Ouagari, K. [1 ]
Pawar, V [2 ]
Coombs, J. [3 ]
Rubin, J. [2 ]
机构：
[1] Novartis Pharmaceut Canada, Dorval, PQ, Canada
[2] I3 Innovus, Medford, MA USA
[3] Novartis, Florham Pk, NJ USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A270 / A270
页数：1
相关论文
共 50 条
  • [31] Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours
    Daniel M. Huse
    Margaret von Mehren
    Gregory Lenhart
    Heikki Joensuu
    Charles Blanke
    Weiwei Feng
    Stan Finkelstein
    George Demetri
    Clinical Drug Investigation, 2007, 27 : 85 - 93
  • [32] Neoadjuvant, adjuvant, and palliative treatment with imatinib in patients with gastrointestinal stromal tumors.
    Nilsson, B. E.
    Sjolund, K.
    Nilsson, E. P.
    Wangberg, B.
    Nilsson, O.
    Ahlman, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
    Goswami, Hardik
    Alsumali, Adnan
    Jiang, Yiling
    Schindler, Matthias
    Duke, Elizabeth R.
    Cohen, Joshua
    Briggs, Andrew
    Puenpatom, Amy
    PHARMACOECONOMICS, 2022, 40 (07) : 699 - 714
  • [34] Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours
    Huse, Daniel M.
    von Mehren, Margaret
    Lenhart, Gregory
    Joensuu, Heikki
    Blanke, Charles
    Feng, Weiwei
    Finkelstein, Stan
    Demetri, George
    CLINICAL DRUG INVESTIGATION, 2007, 27 (02) : 85 - 93
  • [35] Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
    Hardik Goswami
    Adnan Alsumali
    Yiling Jiang
    Matthias Schindler
    Elizabeth R. Duke
    Joshua Cohen
    Andrew Briggs
    Amy Puenpatom
    PharmacoEconomics, 2022, 40 : 699 - 714
  • [36] Approval Summary: Imatinib Mesylate in the Adjuvant Treatment of Malignant Gastrointestinal Stromal Tumors
    Cohen, Martin H.
    Cortazar, Patricia
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2010, 15 (03): : 300 - 307
  • [37] Necrotizing granulomatous disease in patients receiving imatinib mesylate treatment for gastrointestinal stromal tumors (GIST)
    Brueckl, V
    Agaimy, A.
    Ullrich, E.
    Krieg, S.
    Stegmann, A.
    Mackensen, A.
    Meidenbauer, N.
    ONKOLOGIE, 2011, 34 : 252 - 252
  • [38] COST-EFFECTIVENESS ANALYSIS OF SORAFENIB ASSOCIATED TO BEST SUPPORTIVE CARE (BSC) VERSUS BEST SUPPORTIVE CARE ALONE IN THE SECOND LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
    Teich, V
    Fernandes, R. A.
    Schiola, A.
    VALUE IN HEALTH, 2009, 12 (03) : A42 - A42
  • [39] Necrotizing granulomatous disease in patients receiving imatinib mesylate treatment for gastrointestinal stromal tumors (GIST)
    Meidenbauer, N.
    Stegmann, A.
    Mackensen, A.
    Agaimy, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France
    Leeuwenkamp, O.
    Smith-Palmer, J.
    Ortiz, R.
    Werner, A.
    Valentine, W.
    Blachier, M.
    Walter, T.
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1534 - 1541
12345